Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01593124 · ClinicalTrials.gov registry record · Phase 2
Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation
A Phase 2 study, sponsored by CONRAD.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01593124 is a Phase 2 study that has completed, run by CONRAD. The registered enrollment target is 20 participants.
The verdict
NCT01593124, a Phase 2 study, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study investigates the response of vaginal and cervical tissue after exposure to three vaginal products: hydroxyethyl cellulose (HEC) placebo, nonoxynol-9 (N9) and imiquimod (IMQ) cream.
Interventions
- OTHER Placebo
- DRUG Imiquimod
- DRUG Nonoxynol-9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01593124
The ClinicalTrials.gov registry entry for NCT01593124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CONRAD, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01593124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01593124 about?
NCT01593124 is a clinical study titled "Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation". This study investigates the response of vaginal and cervical tissue after exposure to three vaginal products: hydroxyethyl cellulose (HEC) placebo, nonoxynol-9 (N9) and imiquimod (IMQ) cream.
What is the current status of trial NCT01593124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-05. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01593124?
The interventions under investigation include: Placebo (OTHER), Imiquimod (DRUG), Nonoxynol-9 (DRUG).
Who is sponsoring clinical trial NCT01593124?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.